WALTHAM, Mass., June 1 /PRNewswire/ — SynapDx Corp., a new
company focused on developing and commercializing diagnostic
testing for the early detection of autism, announced the completion
of a $9 million Series A financing by
Bain Capital Ventures, General Catalyst Partners, and North Bridge
Venture Partners.
“Autism has a profound effect on children and their families,”
said Stanley N. Lapidus, the
company’s founder, President and Chief Executive Officer.
“The right objective blood-based diagnostic test for autism
may help achieve earlier diagnosis, more rapid intervention, and
improved outcomes.”
About SynapDx Corp.
SynapDx was formed to develop and commercialize blood-based
diagnostic tests for the early detection of autism. SynapDx
was founded by Stanley N. Lapidus,
an experienced life-sciences entrepreneur and inventor with 31
issued patents. Mr. Lapidus founded and led Cytyc Corp.,
EXACT Sciences Corp., and Helicos BioSciences Corp. Mr.
Lapidus’ co-founders of SynapDx Corp. include Jeffrey R. Luber, Esq. and Patrick A. Anquetil, PhD.
‘/>”/>
SOURCE
